MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.560
+0.020 (1.29%)
Apr 28, 2025, 4:00 PM EDT - Market closed
MediciNova Employees
MediciNova had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$849,965
Market Cap
76.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MNOV News
- 14 days ago - MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - GlobeNewsWire
- 20 days ago - First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - GlobeNewsWire
- 5 months ago - MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND - GlobeNewsWire
- 5 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - GlobeNewsWire
- 6 months ago - MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - GlobeNewsWire
- 6 months ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire
- 7 months ago - MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 8 months ago - MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - GlobeNewsWire